Oncology Institute (TOIIW) Invested Capital (2019 - 2026)

Oncology Institute has reported Invested Capital for 8 years, with the latest figure at $62.3 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 21.07% year-over-year to $62.3 million; the trailing twelve-month figure through Mar 2026 stood at $62.3 million (down 21.07% YoY), and the FY2025 full-year result was $61.7 million, down 36.23% from the prior year.
• Invested Capital for Q1 2026 stood at $62.3 million, up from $61.7 million in the prior quarter.
• The five-year high for Invested Capital was $207.0 million in Q3 2022, with the low at $61.7 million in Q4 2025.
• Historically, Invested Capital has averaged $123.7 million across 5 years, with a median of $124.0 million in 2022.
• Annual changes were most pronounced in 2022 — Invested Capital surged 335.49% — and 2025, when it tumbled 44.58%.
• Oncology Institute's Invested Capital stood at $203.8 million in 2022, then retreated by 29.41% to $143.9 million in 2023, then sank by 32.76% to $96.7 million in 2024, then tumbled by 36.23% to $61.7 million in 2025, then increased by 1.05% to $62.3 million in 2026.
• The last three Invested Capital figures came in at $62.3 million (Q1 2026), $61.7 million (Q4 2025), and $63.9 million (Q3 2025), per Business Quant data.